Stock listing
Lang & Schwarz:A0HG6G Orexo AB Aktie
German listing (Lang & Schwarz) of Orexo AB · home listing Stockholm:ORX
Follow Orexo AB into a list and get an email when it puts out news.
Home listing price · OMXSTO:ORX
4.88 SEK -0.23 (-4.5%)
Close on Oct 27, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:ORX
- Day range
- 4.78 – 5.10 SEKOct 27, 2026
- Volume
- 68,424 sharesOct 27, 2026
- Market cap
- 171.4M SEKAt the close on Oct 27, 2026 · price × 35.13M shares outstanding
- 52-week range
- 4.78 – 36.00 SEKLowest and highest trades, Oct 28, 2025 – Oct 27, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:ORX · Home | 4.88 SEK | -0.23 (-4.5%) | 68,424 | 5.10 | 5.10 | 4.78 | 5.11 | Close on Oct 27, 2026 |
| OTC:ORXOF | $0.55 USD | — | 4,000 | $0.55 | $0.55 | $0.55 | — | Close on Oct 22, 2026 |
| OTC:ORXOY | $0.664 USD | 0.000 (0.0%) | — | $0.664 | $0.664 | $0.664 | $0.664 | Close on Oct 27, 2026 |
| Frankfurt:C5G | €0.41 EUR | +0.001 (+0.1%) | — | €0.41 | €0.41 | €0.41 | €0.409 | Close on Oct 27, 2026 |
Daily closes
Last 3 months, Jul 27, 2026 – Oct 27, 2026 · OMXSTO:ORX · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 4.88 | -0.23 | -4.5% | 5.10 | 5.10 | 4.78 | 68,424 | |
| 5.11 | -0.10 | -1.9% | 5.01 | 5.19 | 4.90 | 41,780 | |
| 5.21 | +0.03 | +0.6% | 5.16 | 5.25 | 4.90 | 116,666 | |
| 5.18 | -0.17 | -3.2% | 5.00 | 5.43 | 4.95 | 154,267 | |
| 5.35 | -0.07 | -1.3% | 5.52 | 5.65 | 5.35 | 57,414 | |
| 5.42 | -0.34 | -5.9% | 5.89 | 5.89 | 5.42 | 102,615 | |
| 5.76 | -0.18 | -3.0% | 5.90 | 5.97 | 5.76 | 40,711 | |
| 5.94 | +0.04 | +0.7% | 5.88 | 6.19 | 5.74 | 22,125 | |
| 5.90 | -0.16 | -2.6% | 6.20 | 6.20 | 5.86 | 134,382 | |
| 6.06 | -0.04 | -0.7% | 6.27 | 6.39 | 5.95 | 116,628 | |
| 6.10 | -0.09 | -1.5% | 5.97 | 6.15 | 5.92 | 106,610 | |
| 6.19 | -0.39 | -5.9% | 6.74 | 6.99 | 6.15 | 256,227 | |
| 6.58 | -0.27 | -3.9% | 6.74 | 6.85 | 6.30 | 223,660 | |
| 6.85 | -0.26 | -3.7% | 7.11 | 7.35 | 6.70 | 157,758 | |
| 7.11 | -0.27 | -3.7% | 7.49 | 7.57 | 6.88 | 253,624 | |
| 7.38 | -6.14 | -45.4% | 9.02 | 9.02 | 6.98 | 1,502,331 | |
| 13.52 | +0.12 | +0.9% | 13.60 | 13.86 | 13.10 | 29,141 | |
| 13.40 | -0.34 | -2.5% | 14.28 | 14.28 | 13.30 | 12,555 | |
| 13.74 | -0.02 | -0.1% | 14.72 | 14.72 | 13.74 | 32,302 | |
| 13.76 | +0.30 | +2.2% | 13.50 | 14.80 | 13.16 | 90,662 | |
| 13.46 | +0.16 | +1.2% | 12.90 | 13.50 | 12.80 | 30,421 | |
| 13.30 | +0.12 | +0.9% | 13.18 | 13.30 | 12.90 | 5,584 | |
| 13.18 | +0.38 | +3.0% | 13.08 | 13.52 | 12.76 | 20,859 | |
| 12.80 | +0.30 | +2.4% | 12.80 | 13.08 | 12.54 | 16,148 | |
| 12.50 | -0.10 | -0.8% | 12.68 | 12.70 | 12.50 | 38,672 | |
| 12.60 | -0.10 | -0.8% | 12.66 | 12.70 | 12.20 | 52,276 | |
| 12.70 | -0.10 | -0.8% | 12.78 | 13.20 | 12.54 | 38,675 | |
| 12.80 | -0.04 | -0.3% | 13.00 | 13.02 | 12.80 | 20,269 | |
| 12.84 | +0.10 | +0.8% | 13.22 | 13.22 | 12.72 | 10,200 | |
| 12.74 | -0.20 | -1.5% | 13.00 | 13.10 | 12.72 | 23,102 | |
| 12.94 | -0.10 | -0.8% | 13.42 | 13.42 | 12.94 | 2,757 | |
| 13.04 | -0.24 | -1.8% | 13.30 | 13.86 | 13.04 | 22,485 | |
| 13.28 | -0.12 | -0.9% | 13.64 | 13.64 | 13.00 | 35,980 | |
| 13.40 | +0.10 | +0.8% | 13.74 | 13.80 | 13.22 | 75,077 | |
| 13.30 | -0.48 | -3.5% | 13.78 | 13.80 | 13.20 | 25,899 | |
| 13.78 | -0.92 | -6.3% | 14.70 | 14.92 | 13.62 | 67,592 | |
| 14.70 | -0.44 | -2.9% | 15.44 | 15.44 | 14.50 | 37,583 | |
| 15.14 | -0.26 | -1.7% | 15.50 | 15.50 | 14.64 | 19,314 | |
| 15.40 | +0.16 | +1.0% | 15.48 | 15.48 | 14.66 | 22,080 | |
| 15.24 | +0.18 | +1.2% | 15.26 | 15.88 | 14.64 | 13,800 | |
| 15.06 | -0.64 | -4.1% | 15.84 | 16.60 | 14.64 | 154,190 | |
| 15.70 | +2.32 | +17.3% | 13.90 | 15.70 | 13.40 | 163,007 | |
| 13.38 | +0.28 | +2.1% | 13.80 | 13.80 | 13.20 | 30,738 | |
| 13.10 | -0.16 | -1.2% | 13.08 | 13.44 | 13.00 | 43,736 | |
| 13.26 | -0.28 | -2.1% | 13.88 | 13.88 | 13.00 | 29,433 | |
| 13.54 | +0.14 | +1.0% | 13.40 | 14.08 | 12.90 | 55,022 | |
| 13.40 | -0.46 | -3.3% | 13.76 | 14.14 | 13.14 | 74,241 | |
| 13.86 | -0.16 | -1.1% | 14.02 | 14.46 | 13.50 | 36,317 | |
| 14.02 | -0.48 | -3.3% | 14.62 | 14.90 | 13.90 | 30,807 | |
| 14.50 | -0.38 | -2.6% | 15.12 | 15.12 | 14.38 | 51,198 | |
| 14.88 | -0.76 | -4.9% | 15.30 | 15.78 | 14.50 | 26,580 | |
| 15.64 | +0.44 | +2.9% | 15.20 | 15.90 | 15.18 | 2,202 | |
| 15.20 | -0.46 | -2.9% | 15.38 | 15.38 | 15.10 | 13,080 | |
| 15.66 | +0.02 | +0.1% | 15.62 | 15.84 | 14.82 | 22,726 | |
| 15.64 | +1.12 | +7.7% | 14.40 | 16.12 | 14.38 | 63,436 | |
| 14.52 | -0.38 | -2.6% | 14.86 | 14.88 | 14.22 | 22,844 | |
| 14.90 | +0.22 | +1.5% | 14.62 | 14.94 | 14.62 | 8,267 | |
| 14.68 | +0.34 | +2.4% | 14.36 | 14.98 | 14.28 | 24,885 | |
| 14.34 | -0.02 | -0.1% | 14.40 | 14.50 | 14.12 | 43,533 | |
| 14.36 | -0.34 | -2.3% | 14.68 | 14.96 | 14.26 | 47,738 | |
| 14.70 | +0.22 | +1.5% | 15.00 | 15.00 | 14.34 | 18,124 | |
| 14.48 | -0.22 | -1.5% | 14.90 | 14.90 | 14.48 | 27,813 | |
| 14.70 | +0.10 | +0.7% | 15.00 | 15.00 | 14.32 | 55,246 | |
| 14.60 | +0.24 | +1.7% | 14.18 | 14.70 | 13.70 | 108,507 | |
| 14.36 | -0.74 | -4.9% | 14.68 | 15.06 | 14.12 | 63,413 | |
| 15.10 | 0.00 | 0.0% | 15.02 | 15.36 | 14.56 | 21,941 | |
| 15.10 | -0.14 | -0.9% | 15.26 | 15.52 | 15.00 | 51,217 |
- Ticker
- Lang & Schwarz:A0HG6G
- Asset type
- Stock
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Oct 14, 2026
Orexo reports encouraging bioavailability in first in vivo study of oral semaglutide formulation based on AmorphOX
Latest earnings call · Oct 22, 2026
Orexo (Stockholm:ORX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 31, 2026
DNB Carnegie Small Cap Day 2026
Conference · 15 slides
Calls
Replays
Orexo (Stockholm:ORX) Q3 2026 Earnings Call
Thu, Oct 22, 2026 · 8:00 AM ET
Watch TranscriptOrexo (Stockholm:ORX) Q2 2026 Earnings Call
Thu, Jul 16, 2026 · 8:00 AM ET
Watch TranscriptOrexo (Stockholm:ORX) Q1 2026 Earnings Call
Tue, Apr 28, 2026 · 8:00 AM ET
Watch Transcript
Latest news
Orexo reports encouraging bioavailability in first in vivo study of oral semaglutide formulation based on AmorphOX
Oct 14, 2026
Closed 6.06 (-0.7%) on Oct 14, 2026
Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice
Aug 31, 2026
Closed 15.06 (-4.1%) on Sep 1, 2026
Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships
Jun 9, 2026
Closed 19.70 (+4.1%) on Jun 9, 2026
Orexo announces positive outcome from an in-vivo study of OX390
May 19, 2026
Closed 18.80 (+2.1%) on May 19, 2026
Earnings Call Q1 2026 (engelska)
Apr 28, 2026
Closed 19.30 (-3.1%) on Apr 28, 2026
Earnings Call Q1 2026
Apr 28, 2026
Closed 19.30 (-3.1%) on Apr 28, 2026
Q1 2026 Interim Report MASTER
Apr 28, 2026
Closed 19.30 (-3.1%) on Apr 28, 2026
Q1 2026 Interim Report 2026
Apr 28, 2026
Closed 19.30 (-3.1%) on Apr 28, 2026
Orexo Q1 2026 Interim Report
Apr 28, 2026
Closed 19.30 (-3.1%) on Apr 28, 2026
Invitation to presentation of Orexo´s Q1 2026 Interim Report
Apr 21, 2026
Closed 21.40 (+4.4%) on Apr 21, 2026
Decks
DNB Carnegie Small Cap Day 2026
Conference · 15 slides · Aug 31, 2026
Q2 2026 Earnings Presentation
Earnings · 18 slides · Jul 16, 2026
ABGSC Investor Day 2026
Conference · 14 slides · May 22, 2026
Q1 2026 Earnings Presentation
Earnings · 13 slides · Apr 28, 2026
Orexo AB on 6ix
- News releases
- 16 in the last 12 months · 19 in all · newest Oct 14, 2026 · oldest 2025
- Calls
- 11 calls with a replay · 11 with a transcript · latest Oct 22, 2026
- Decks
- 28 decks · latest Aug 31, 2026
Where Orexo AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:ORX · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A0HG6G | LS Exchange | Germany | EUR |
| LSIN:0H19 | LSIN | United Kingdom | SEK |
| Lang & Schwarz:A0HG6G · This page | Lang & Schwarz | Germany | EUR |
| OTC:ORXOF | OTC | United States | USD |
| OTC:ORXOY | OTC | United States | USD |
| Aquis:ORXS | Aquis | United Kingdom | SEK |
| Aquis:ORXS | Aquis | United Kingdom | SEK |
| Frankfurt:C5G | Frankfurt | Germany | EUR |
| Stuttgart:C5G | Stuttgart | Germany | EUR |
| Turquoise:ORXS | Turquoise | United Kingdom | SEK |
Log in to ask 6ix AI your own questions about Orexo AB.